Targets › CD2
3 programs from 3 companies in 7 trials: 5 Phase 1, 2 Phase 2; Oncology, Gastroenterology, Genitourinary; next expected readout May 2027.
CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function. (UniProt, P06729)
Open in Phaseline: the race on CD2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nefro Avillion Clinical Development | Siplizumab T-cell surface antigen CD2 inhibitor | CD2 | Phase 2 | Renal Transplant Failure and Rejection; Autoimmune Liver Disease; Renal Failure; Kidney Failure | Mar 2028 |
| ITB-Med | Siplizumab (TCD601) T-cell surface antigen CD2 inhibitor | CD2 | Phase 2 | Liver Transplantation | Jun 2029 |
| Memorial Sloan Kettering Cancer Center | Antithymocyte globulin (ATG) Polyclonal antibody targeting T lymphocytes; immunosuppressant | CTLA4, CD2, CD3, CD4, CD8 | Phase 1 | Myeloid Diseases; Hematologic Malignancies | May 2027 |
Myeloid Diseases (1) Hematologic Malignancies (1) Renal Transplant Failure and Rejection (1) Autoimmune Liver Disease (1) Renal Failure (1) Kidney Failure (1) Liver Transplantation (1)
mixed (2), small molecule (1)
Memorial Sloan Kettering Cancer Center (1) Nefro Avillion Clinical Development (1) ITB-Med (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.